BioCentury
ARTICLE | Clinical News

Achillion preclinical data

December 3, 2012 8:00 AM UTC

In vitro, ACH-2684 provided higher potency than asunaprevir from Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) against both HCV genotypes 1a and 1b infection. Additionally, the combination of A...